EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma

Szonja Anna Kovács iD, Tamás Kovács, András Lánczky, Ágnes Paál, Zsombor I Hegedűs, Nabil V Sayour, Lilla Szabó, Andrea Kovács, Giampaolo Bianchini, Péter Ferdinandy, Alberto Ocana, Zoltán V Varga iD und 2 weitere

British Journal of Pharmacology · 2025-08 · 182 (16) · 3903-3922

DOI: 10.1111/bph.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 05.05.2025. Verfasst von Szonja Anna Kovács und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: YAP-Signaling Proteins, Immune Checkpoint Inhibitors, Skin Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research, Development and Innovation Office, European Union's Horizon 2020 Research and Innovation Programme, Momentum Research Grant from the Hungarian Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Immune checkpoint inhibitors, such as anti­PD1, revolutionized melanoma treatment. However, resistance and low response rates remain problems. Our goal was to pinpoint actionable biomarkers of resistance to anti‐PD1 treatment and verify therapeutic effectiveness in vivo. Experimental Approach Using receiver operating characteristic (ROC) and survival analysis in a database of 1434 samples, we identified the strongest resistance‐associated genes. Inhibitors were evaluated in C57BL/6J mice using wild‐type B16­F10, and BRAF, ‐PTEN, ‐CDKN2A‐mutant YUMM1.7 melanoma cell lines. We investigated the synergistic impact of anti­PD1 therapy and yes­associated protein 1 (YAP1) inhibition by non‐photoactivated Verteporfin. Tumour volume was determined at fixed cutoff points, normalized to body weights. Key Results In the anti­PD1­treated melanoma cohort, YAP1 was the strongest druggable candidate overexpressed in non­responder patients (ROC AUC = 0.699, FC = 1.8, P=1.1E−8 ). The baseline YAP1 expression correlated with worse progression‐free survival (HR = 2.51, P=1.2E−6, FDR = 1%), and overall survival (HR = 2.15, P = 1.2E−5, FDR = 1%). In YUMM1.7, combination of Verteporfin plus anti‐PD1 reduced tumour size more than anti‐PD1 monotherapy ( P=0.008 ), or control ( P=0.021 ). There was no difference between the cohorts in B16­F10 inoculated mice. We found increased expression of YAP1 in YUMM1.7 mice compared to B16‐F10. The combination therapy induced a more‐immune‐inflamed phenotype characterized by increased expression of T cell and M1 macrophage markers. Conclusions and Implications Verteporfin with anti‐PD1 exhibited antitumor potential by promoting a pro‐inflammatory tumour microenvironment in melanoma. We believe that YAP1 acts as a master regulator of anti‐PD1 resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

YAP-Signaling ProteinsImmune Checkpoint InhibitorsSkin NeoplasmsDrug Resistance, NeoplasmMelanomaProgrammed Cell Death 1 ReceptorAdaptor Proteins, Signal TransducingTranscription FactorsAnimalsMiceMice, Inbred C57BLHumansCell Line, TumorVerteporfinFemaleMelanoma, Experimental

Stichwörter der Autor:innen

VerteporfinYAP1anti‐PD1cancer immunotherapycombination therapyimmune checkpoint inhibitormelanomaskin cancer

Substanzen

YAP-Signaling ProteinsImmune Checkpoint InhibitorsYAP1 protein, humanVerteporfinYap1 protein, mouseProgrammed Cell Death 1 ReceptorAdaptor Proteins, Signal TransducingTranscription Factors

Autor:innen und Institutionen

  • Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
  • Oncology Biomarker Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
  • National Laboratory for Drug Research and Development, Budapest, Hungary.
  • Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Center for Pharmacology and Drug Research & Development, Budapest, Hungary.
  • HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary.

ORCID-Profile: Szonja Anna Kovács, Zoltán V Varga

Förderung

  • National Research, Development and Innovation Office
  • European Union's Horizon 2020 Research and Innovation Programme
  • Momentum Research Grant from the Hungarian Academy of Sciences
  • Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Zitieren

APA

Kovács, S. A., Kovács, T., Lánczky, A., Paál, Á., Hegedűs, Z. I., Sayour, N. V., Szabó, L., Kovács, A., Bianchini, G., Ferdinandy, P., Ocana, A., Varga, Z. V., Fekete, J. T., & Győrffy, B. (2025). Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma. British Journal of Pharmacology, 182(16), 3903-3922. https://doi.org/10.1111/bph.70052

Vancouver

Kovács SA, Kovács T, Lánczky A, Paál Á, Hegedűs ZI, Sayour NV, et al. Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma. British Journal of Pharmacology. 2025;182(16):3903-3922. doi:10.1111/bph.70052

BibTeX
@article{Kovcs2025,
  author = {Kovács, Szonja Anna and Kovács, Tamás and Lánczky, András and Paál, Ágnes and Hegedűs, Zsombor I and Sayour, Nabil V and Szabó, Lilla and Kovács, Andrea and Bianchini, Giampaolo and Ferdinandy, Péter and Ocana, Alberto and Varga, Zoltán V and Fekete, János Tibor and Győrffy, Balázs},
  title = {Unlocking the power of immune checkpoint inhibitors: Targeting YAP1 reduces anti‐PD1 resistance in skin cutaneous melanoma},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {16},
  pages = {3903--3922},
  doi = {10.1111/bph.70052}
}
Kostenlos starten →